| HOME >> BIOLOGY >> TECHNOLOGY |
LONDON, June 18 /PRNewswire/ --
- Speciality Urology Company Gains Exclusive UK Distribution Rights
Speciality European Pharma Limited (SEP), the UK based, urology focused, specialty pharmaceutical company, is pleased to announce that it will obtain the exclusive distribution rights to Regurin(R) (trospium chloride) for the UK and Ireland, as of the 1st July 2009. Regurin, owned by Rottapharm-Madaus, is currently marketed under different brand names in European countries including Germany, Italy, Austria, Spain and Switzerland.
Regurin is licensed for use in men and women to treat the symptoms of urge incontinence and/or increased urinary frequency and urgency as may occur in patients with overactive bladder (OAB). Urinary incontinence is an embarrassing problem estimated to affect over a third of women over 40[1]. Regurin is an anti-muscarinic, which reduces the contractions of the detrusor muscle in the bladder and increases bladder capacity.[2] It is well tolerated with a low incidence of the common anti-muscarinic side effect, dry mouth.[3],[4] Regurin also does not cross the blood-eye or blood-brain barrier[5],[6],[7] reducing the incidence of confusion in people taking this treatment.[8],[9],[10],[11]
"Trospium chloride is central to managing certain types of urinary
incontinence and is one of the recommended options by the National Institute
for Health and Clinical Excellence (NICE) for use in women with mixed urinary
incontinence of OAB after generic oxybutynin," said Professor Linda Cardozo,
Commenting on the deal, Geoff McMillan, Chief Executive Officer of SEP,
said: "This agreement provides us with a well established and clinically
superior product in the field of urology, an area that remains the focus of
our company. This deal demonstrates our
'/>"/>
| SOURCE Speciality European Pharma Copyright©2009 PR Newswire. All rights reserved |
Related biology technology :
1. SleepQuest Signs National Contract With Aetna
2. A-Power Energy Generation Systems Ltd. Signs a Biomass-Based DG Contract with Sanmenxia New Energy Bio-Electricity Co., Ltd.
3. Insmed CEO Resigns Due to Health Concerns
4. NeoStem Signs Agreement with Shanghai Corporation to Develop A Stem Cell Collection and Treatment Network in Shanghai, Taiwan and Other Targeted China Provinces
5. Guy J. Quigley Resigns as Chairman and CEO of The Quigley Corporation: Quigley Leaves Company He Founded 20 Years Ago
6. LNA-Based HIF-1 Alpha Inhibitor Shows Early Signs of Clinical Benefit
7. Prometheus Research Signs 3-Year Contract With Simons Foundation to Expand HTSQL Informatics System for Autism Research
8. Assay Designs(TM), Inc. Announces Release of First Available Product for Multiplex Analysis of Heat Shock Proteins
9. Microsoft Signs Agreement With Merck & Co. Inc. to Acquire Assets of Rosetta Biosoftware, Strengthening Position in Life Sciences Industry
10. ZyGEM Corp. Signs Agreement to Incorporate Its Breakthrough DNA Extraction Technology Into Rubicons Research and Diagnostic Products
11. China Sky One Medical, Inc. Signs Agreement with Taiwan Golden Biotechnology Corp. on Development of New Anti-Cancer Drug
| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |